search
Back to results

The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation

Primary Purpose

Liver Transplantation

Status
Terminated
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Glucose/Ischemic Preconditioning Pre-treatment
Sponsored by
University Health Network, Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Liver Transplantation focused on measuring Liver Disease, Transplantation

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Recipient 18 years of age or older
  • Recipient with chronic end-stage liver disease
  • Deceased donor liver transplant
  • Recipient capable of providing written informed consent
  • Whole organ graft from donors aged 60 years or older

Exclusion Criteria:

  • Fulminant liver failure
  • Objection by any other member of the retrieval team
  • Split-liver grafts
  • Donor that has received total parenteral nutrition within 24hr of organ retrieval Donors from whom the pancreas and/or small bowel are also being retrieved

Sites / Locations

  • University Health Network (Toronto General Hospital)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

1

2

Arm Description

Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ

Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.

Outcomes

Primary Outcome Measures

Reperfusion injury determined by peak AST

Secondary Outcome Measures

Biliary Complications, infection and rejection
graft and patient survival; length of hospital stay; length of ICU stay
Liver ATP and glycogen content; blood cytokine levels; liver gene expression of pro- and anti-apoptotic genes

Full Information

First Posted
July 16, 2008
Last Updated
July 24, 2014
Sponsor
University Health Network, Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT00718575
Brief Title
The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation
Official Title
A Prospective, Randomized Trial to Investigate the Effects of Glucose/ Ischemic Preconditioning Donor Pre-treatment on Reperfusion Injury in Deceased-Donor Liver Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2012
Overall Recruitment Status
Terminated
Why Stopped
too few patients meeting current eligibility criteria
Study Start Date
August 2008 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Health Network, Toronto

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Standard liver retrieval procedures for transplantation from a deceased donor inevitably result in a "reperfusion injury" to the liver tissue. The purpose of this research study is to find out whether treatment of the liver with a "preconditioning" protocol before its removal from the donor will help reduce any of this injury. The "preconditioning" treatment being tested has two components. Firstly, a solution of glucose+insulin is infused and secondly, blood flow to the liver is stopped briefly (10 minutes) and then resumed. Both strategies, individually, have been shown to reduce liver tissue injury in human studies. We hypothesize that combining both strategies will have a clinical benefit to patients and will improve liver function following transplant.
Detailed Description
Liver transplantation is the only chance of cure for patients with end-stage liver disease. Unfortunately, standard organ preservation results in an ischemic-reperfusion injury (IRI) at the time of graft implantation. Novel strategies have been proposed to decrease reperfusion injury and improve graft function. This study will be the first to combine both strategies in a randomized, prospective trial. The intervention will occur during the retrieval surgery prior to cold preservation. Briefly, a glucose and insulin solution will be infused via the mesenteric vein at a controlled rate. Immediately prior to cross-clamping, blood supply to the liver will be restricted for 10 minutes and then resumed for 10 minutes before beginning cold preservation. All remaining surgical procedures, including the recipient surgery, will be performed by standard techniques. The liver recipient does not directly receive any intervention during this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Transplantation
Keywords
Liver Disease, Transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
Arm Title
2
Arm Type
No Intervention
Arm Description
Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
Intervention Type
Procedure
Intervention Name(s)
Glucose/Ischemic Preconditioning Pre-treatment
Intervention Description
A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
Primary Outcome Measure Information:
Title
Reperfusion injury determined by peak AST
Time Frame
first 24 hours post-operative
Secondary Outcome Measure Information:
Title
Biliary Complications, infection and rejection
Time Frame
first month post-transplantation
Title
graft and patient survival; length of hospital stay; length of ICU stay
Time Frame
30 days and 90 days post-transplantation
Title
Liver ATP and glycogen content; blood cytokine levels; liver gene expression of pro- and anti-apoptotic genes
Time Frame
immediately pre-removal and post- transplantation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Recipient 18 years of age or older Recipient with chronic end-stage liver disease Deceased donor liver transplant Recipient capable of providing written informed consent Whole organ graft from donors aged 60 years or older Exclusion Criteria: Fulminant liver failure Objection by any other member of the retrieval team Split-liver grafts Donor that has received total parenteral nutrition within 24hr of organ retrieval Donors from whom the pancreas and/or small bowel are also being retrieved
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Markus Selzner, M.D.
Organizational Affiliation
University Health Network, Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Health Network (Toronto General Hospital)
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2N2
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation

We'll reach out to this number within 24 hrs